Trial Profile
A Phase 1/2 Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) in Combination With Lenalidomide (LEN) With and Without Dexamethasone (DEX)in Subjects With Newly Diagnosed Multiple Myeloma (NDMM)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 13 Nov 2022 Planned number of patients changed from 121 to 138.
- 22 Sep 2022 Status changed from active, no longer recruiting to completed.
- 11 May 2022 Planned End Date changed from 13 Sep 2022 to 6 Sep 2022.